Pill Connect dispenser supports clinical trial for personalized Tuberculosis care.
Pill Connect has announced the completion of its first clinical trial in collaboration with the University Medical Center Groningen in the Netherlands.
Utilising Pill Connect’s Smart Dispenser technology, the study aimed to investigate if Digital Adherence Technology (DAT) is feasible as a novel tool to monitor medication adherence and guide Therapeutic Drug Monitoring (TDM) in patients with Tuberculosis (TB).
The standard treatment regimen for drug-susceptible TB takes 6-9 months and requires daily intake of multiple medications under the observation of a healthcare professional. However, this approach increases the cost of treatment exponentially, and presents real challenges in terms of patient wellbeing, with cure rates and outcomes continuing to remain suboptimal.
The study, to be published in the European Respiratory Journal, comprised of ten hospitalised TB patients who used DAT to self-administer a solid oral dose drug for 14 days of their TB treatment, with an overall dispense adherence of 99% being reported. This was a first clinical proof-of-concept study that evaluated the combined use of DAT and saliva sampling for TDM among TB patients in a hospital setting, showing that TB patients can use DAT with acceptable reliability.
Read more about the study here.